Successful Neoadjuvant Treatment Using Trastuzumab Emtansine (Kadcyla) for Locally Advanced and Metastatic Lacrimal Gland Adenocarcinoma.

IF 1.2 4区医学 Q3 OPHTHALMOLOGY

Ophthalmic Plastic and Reconstructive Surgery Pub Date : 2025-05-07 DOI:10.1097/IOP.0000000000002967

Agni Kakouri, Matthew J Debnam, Renata Ferrarotto, Tracy Lu, Bita Esmaeli

引用次数: 0

Abstract

A 25-year-old man presented with a locally advanced lacrimal gland adenocarcinoma with parotid metastasis. The lesion was strongly HER-2 positive (3+) on immunohistochemistry. The patient was treated with neoadjuvant trastuzumab emtansine, an antibody-drug conjugate targeting HER-2. The patient had an excellent response to neoadjuvant therapy trastuzumab emtansine, with a significant decrease in the size of the lacrimal gland carcinoma, making eye-sparing surgery a viable option for the patient. Furthermore, there was nearly complete resolution of the parotid metastasis; thus, radical neck dissection and parotidectomy were avoided.

查看原文本刊更多论文

曲妥珠单抗Emtansine （Kadcyla）成功用于局部晚期和转移性泪腺癌的新辅助治疗。

一个25岁的男性提出了局部晚期泪腺腺癌伴腮腺转移。免疫组化显示HER-2强阳性（3+）。患者接受新辅助曲妥珠单抗emtansine治疗，这是一种靶向HER-2的抗体-药物偶联物。患者对新辅助治疗曲妥珠单抗emtansine有极好的反应，泪腺癌的大小显着减少，使保眼手术成为患者的可行选择。此外，腮腺转移几乎完全消除；因此，避免了根治性颈部清扫和腮腺切除术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic Plastic and Reconstructive Surgery 医学-外科

CiteScore

2.50

自引率

10.00%

发文量

322

审稿时长

3-8 weeks

期刊介绍： Ophthalmic Plastic and Reconstructive Surgery features original articles and reviews on topics such as ptosis, eyelid reconstruction, orbital diagnosis and surgery, lacrimal problems, and eyelid malposition. Update reports on diagnostic techniques, surgical equipment and instrumentation, and medical therapies are included, as well as detailed analyses of recent research findings and their clinical applications.